Molecular Therapy: Oncolytics | |
Multiple targeted self-emulsifying compound RGO reveals obvious anti-tumor potential in hepatocellular carcinoma | |
Shaorong Tian1  Ke Xu2  Junhao Mu3  Hongyi Chen4  Sanxiu He5  Jiong Chen6  Tingxiu Xiang6  Qin Xiang6  Yue Wu6  Jialin Chen6  Yijiao Ning6  Xiaoqian He6  Xin Le6  | |
[1] Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China;Technology, Chongqing, China;;Chongqing College of Humanities, Science &Chongqing Traditional Chinese Medicine Hospital, Chongqing, China;Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China;Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; | |
关键词: hepatocellular carcinoma; ginsenoside Rg3; ganoderma lucidum polysaccharide; oridonin; epidermal growth factor receptor; | |
DOI : | |
来源: DOAJ |
【 摘 要 】
Hepatocellular carcinoma (HCC) is a highly vascularized, inflammatory, and abnormally proliferating tumor. Monotherapy is often unable to effectively and comprehensively inhibit the progress of HCC. In present study, we selected ginsenoside Rg3, ganoderma lucidum polysaccharide (GLP), and oridonin as the combined therapy. These three plant monomers play important roles in anti-angiogenesis, immunological activation, and apoptosis promotion, respectively. However, the low solubility and poor bioavailability seriously hinder their clinical application. To resolve these problems, we constructed a new drug, Rg3, GLP, and oridonin self-microemulsifying drug delivery system (RGO-SMEDDS). We found that this drug effectively inhibits the progression of HCC by simultaneously targeting multiple signaling pathways. RGO-SMEDDS restored immune function by suppressing the production of immunosuppressive cytokine and M2-polarized macrophages, reduced angiogenesis by downregulation of vascular endothelial growth factor and its receptor, and retarded proliferation by inhibiting the epidermal growth factor receptor EGFR/AKT/epidermal growth factor receptor/protein kinase B/glycogen synthase kinase-3 (GSK3) signaling pathway. In addition, RGO-SMEDDS showed considerable safety in acute toxicity tests. Results from this study show that RGO-SMEDDS is a promising therapy for the treatment of HCC.
【 授权许可】
Unknown